Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott, William Wesson, Pilar Thangwaritorn, Raeef L Rahman, Forat Lutfi, Marc Hoffmann, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 389.

https://doi.org/10.1182/blood-2024-205983

Published: 2024

Journal Articles

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Jordan Snyder, Dennis Grauer, Nausheen Ahmed, Al-Ola Abdallah, Marc Hoffmann, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 935.

https://doi.org/10.1182/blood-2024-199893

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review

Moazzam Shahzad, Hana Qasim, Ben Ponvilawan, Muhammad Kashif Amin, Fizza Zulfiqar, Areeba Ismail, Muhammad Uzair Ishaq, Sohaib Irfan, Abhinav Vyas, Ibrahim Khamees, Rida Ihsan, Sibgha Gull Chaudhary, Iqra Anwar, Nausheen Ahmed, Leyla O. Shune, Al-Ola Abdallah, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7237.

https://doi.org/10.1182/blood-2024-198825

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Journal Articles

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Joseph G Bennett, Kamen Kossow, Leah Diebolt, Nicole Twardowski, Jianzheng Wu, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Brian Hess, James A Davis, Al-Ola Abdallah, Nausheen Ahmed, Joseph P. McGuirk, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 6556.

https://doi.org/10.1182/blood-2024-201728

Published: 2024

Journal Articles

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Blood (2024) 144 (Supplement 1): 7242.

https://doi.org/10.1182/blood-2024-206536

Published: 2024

Journal Articles

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

Emily J Casteen, Lauren N Scott, Raeef L Rahman, Zahra Mahmoudjafari, Faiz Anwer, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Al-Ola Abdallah, Shebli Atrash, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7950.

https://doi.org/10.1182/blood-2024-204130

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Jordan Snyder, Nausheen Ahmed, Aqeeb Ur Rehman, Muhammad Umair Mushtaq, Aung M. Tun, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7731.

https://doi.org/10.1182/blood-2024-207753

Published: 2024

Journal Articles

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Bone Marrow Transplantation

Sibgha Gull Chaudhary, Moazzam Shahzad, Iqra Anwar, Sohaib Irfan, Muhammad Kashif Amin, Matthew McGuirk, Shaun DeJarnette, Nausheen Ahmed, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7424.

https://doi.org/10.1182/blood-2024-198378

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Raeef L Rahman, Jianzheng Wu, Lauren N Scott, William Wesson, Razan Mansour, Aung M. Tun, Marc Hoffmann, Al-Ola Abdallah, Dinesh Pal Mudaranthakam, Joseph P. McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7099.

https://doi.org/10.1182/blood-2024-205978

Published: 2024

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation

Moazzam Shahzad, Aleenah Mohsin, Aqeeb Ur Rehman, Sohaib Irfan, Muhammad Atif Khan, Muhammad Kashif Amin, Matthew McGuirk, Sibgha Gull Chaudhary, Faiza Humayun Khan, Iqra Anwar, Nausheen Ahmed, Al-Ola Abdallah, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7421.

https://doi.org/10.1182/blood-2024-193485

Published: 2024

Journal Articles

Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Muhammad Umair Mushtaq, Amir Kasaeian, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Aqeeb Ur Rehman, Sibgha Gull Chaudhary, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2024-199559

Published: 2024

Journal Articles

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Blood (2024) 144 (Supplement 1): 5170.5.

https://doi.org/10.1182/blood-2024-211053

Published: 2024

Journal Articles

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 5170.4.

https://doi.org/10.1182/blood-2024-211018

Published: 2024

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis

Muhammad Umair Mushtaq, Amir Kasaeian, Sibgha Gull Chaudhary, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Iqra Anwar, Sohaib Irfan, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2024-200031

Published: 2024

Journal Articles

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Blood (2024) 144 (Supplement 1): 497.

https://doi.org/10.1182/blood-2024-198669

Published: 2024

Journal Articles

Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Muhammad Umair Mushtaq, Amir Kasaeian, Sibgha Gull Chaudhary, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Iqra Anwar, Ahmad Basharat, Matthew McGuirk, Peiman Hematti, Al-Ola Abdallah, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2024-200022

Published: 2024

Journal Articles

Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients

Blood (2024) 144 (Supplement 1): 7414.

https://doi.org/10.1182/blood-2024-206235

Published: 2024

NARROW

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Bone Marrow Transplantation

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation

Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only